Ironwood Pharmaceuticals Inc. (IRWD)
Nasdaq · Pharmaceutical Preparations · Manufacturing · CIK 1446847 · fiscal year ends in Dec
Closing price $3.62 on 29 Oct 2026; 52-week range $1.50 to $5.39.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $389.3M
- Revenue growth
- 26.2%
- Net income, last twelve months
- $129.9M
- Earnings per share
- $0.77
- Operating margin
- 60.1%
- Net margin
- 33.4%
- Market value
- $598.2M
- Price to earnings
- 4.7x
- Cash
- $79.1M
- Debt
- $385.0M
- Shares outstanding
- 165.2M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $296.2M | $98.5M | $24.0M | $0.15 | $127.0M | 10-K filed 26 Feb 2026 |
| FY2024 | 31 Dec 2024 | $351.4M | $93.1M | $880.0K | $0.01 | $103.4M | 10-K filed 31 Mar 2025 |
| FY2023 | 31 Dec 2023 | $442.7M | -$945.4M | -$1.0B | -$6.45 | $183.2M | 10-K filed 16 Feb 2024 |
| FY2022 | 31 Dec 2022 | $410.6M | $250.3M | $175.1M | $0.96 | $273.6M | 10-K filed 16 Feb 2023 |
| FY2021 | 31 Dec 2021 | $413.8M | $232.3M | $528.4M | $3.21 | $261.6M | 10-K filed 18 Feb 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $113.0M | $51.3M | $0.31 |
| Q1 FY2026 | 31 Mar 2026 | $106.5M | $40.8M | $0.24 |
| Q4 FY2025 | 31 Dec 2025 | $47.7M | -$2.3M | -$0.01 |
| Q3 FY2025 | 30 Sep 2025 | $122.1M | $40.1M | $0.23 |
| Q2 FY2025 | 30 Jun 2025 | $85.2M | $23.6M | $0.14 |
| Q1 FY2025 | 31 Mar 2025 | $41.1M | -$37.4M | -$0.23 |
| Q4 FY2024 | 31 Dec 2024 | $90.5M | $2.3M | $0.03 |
| Q3 FY2024 | 30 Sep 2024 | $91.6M | $3.6M | $0.02 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By product, FY2025
| Segment | Revenue | Share |
|---|---|---|
| Collaborative arrangements revenue | $296.2M | 100.0% |
| Collaborative arrangement, other agreements | $87.0K | 0.0% |
Company events
The newest 8-K filings of 197 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 16 Oct 2026 | 8-K | Leadership change | 5.02, 9.01 |
| 6 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 18 Jun 2026 | 8-K | Leadership change, Shareholder vote | 5.02, 5.07, 9.01 |
| 15 Jun 2026 | 8-K | Other events | 8.01 |
| 21 May 2026 | 8-K/A | Leadership change | 5.02 |
| 13 May 2026 | 8-K | Leadership change | 5.02 |
| 7 May 2026 | 8-K | Results | 2.02, 9.01 |
| 11 Mar 2026 | 8-K | Other events | 8.01 |
| 25 Feb 2026 | 8-K | Results | 2.02, 9.01 |
| 2 Jan 2026 | 8-K | Results | 2.02, 9.01 |
| 23 Dec 2025 | 8-K | Material agreement, Other events | 1.01, 8.01, 9.01 |
| 26 Nov 2025 | 8-K | Other events | 8.01 |
Every filing
The newest filings with the SEC of 402 held.
| Filed | Form | Period |
|---|---|---|
| 16 Oct 2026 | 8-K | 12 Oct 2026 |
| 6 Aug 2026 | 10-Q | 30 Jun 2026 |
| 6 Aug 2026 | 8-K | 6 Aug 2026 |
| 18 Jun 2026 | 8-K | 16 Jun 2026 |
| 15 Jun 2026 | 8-K | 15 Jun 2026 |
| 21 May 2026 | 8-K/A | 8 May 2026 |
| 13 May 2026 | 8-K | 8 May 2026 |
| 7 May 2026 | 10-Q | 31 Mar 2026 |
| 7 May 2026 | 8-K | 7 May 2026 |
| 28 Apr 2026 | ARS | 31 Dec 2025 |
| 28 Apr 2026 | DEFA14A | – |
| 28 Apr 2026 | DEF 14A | 16 Jun 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 7 Jul 2026 | Silver Ronald, PFO & PAO | Sale under a trading plan | 127,890 | $4.52 | $578.1K | 313,680 | 9 Jul 2026 |
| 16 Jun 2026 | Mchugh Julie, Director | Sale under a trading plan | 21,571 | $3.73 | $80.5K | 250,749 | 17 Jun 2026 |
| 17 Mar 2026 | Denner Alexander J, Director | Sale outside a trading plan | 6,725,000 | $3.05 | $20.5M | 9,194,435 | 17 Mar 2026 |
| 17 Mar 2026 | Denner Alexander J, Director | Sale outside a trading plan | 5,800 | $3.31 | $19.2K | 9,188,635 | 17 Mar 2026 |
| 24 Feb 2026 | John Minardo, Chief Legal Officer | Sale outside a trading plan | 19,053 | $3.66 | $69.7K | 363,886 | 25 Feb 2026 |
| 24 Feb 2026 | Shetzline Michael, SVP, CMO, Head-Res&Drug | Sale outside a trading plan | 17,012 | $3.66 | $62.3K | 521,425 | 25 Feb 2026 |
| 24 Feb 2026 | Gaskins Tammi L, Chief Commercial Officer | Sale outside a trading plan | 11,239 | $3.66 | $41.1K | 213,738 | 25 Feb 2026 |
| 24 Feb 2026 | Mccourt Thomas A, Chief Executive Officer | Sale outside a trading plan | 103,526 | $3.66 | $378.9K | 1,489,002 | 25 Feb 2026 |
| 24 Feb 2026 | Martini Gregory S., Chief Financial Officer | Sale outside a trading plan | 11,457 | $3.66 | $41.9K | 160,601 | 25 Feb 2026 |
| 24 Feb 2026 | Silver Ronald, Principal Accounting Officer | Sale outside a trading plan | 12,621 | $3.66 | $46.2K | 252,636 | 25 Feb 2026 |
| 23 Feb 2026 | John Minardo, Chief Legal Officer | Sale outside a trading plan | 17,439 | $3.81 | $66.4K | 382,939 | 25 Feb 2026 |
| 23 Feb 2026 | Shetzline Michael, SVP, CMO, Head-Res&Drug | Sale outside a trading plan | 15,570 | $3.81 | $59.3K | 538,437 | 25 Feb 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 23 Sep 2026 | Shetzline Michael, Former Officer | 83,306 | $377.4K | 24 Sep 2026 |
| 7 Jul 2026 | RONALD SILVER, Officer | 127,890 | $560.2K | 7 Jul 2026 |
| 16 Jun 2026 | JULIE MCHUGH, Director | 21,571 | $79.6K | 16 Jun 2026 |
| 20 Feb 2026 | Gaskins Tammi L, Officer | 19,775 | $91.2K | 23 Feb 2026 |
| 20 Feb 2026 | Martini Gregory S., Officer | 20,163 | $93.0K | 23 Feb 2026 |
| 20 Feb 2026 | Shetzline Michael, Officer | 29,937 | $138.0K | 23 Feb 2026 |
| 20 Feb 2026 | John Minardo, Officer | 33,528 | $154.6K | 23 Feb 2026 |
| 20 Feb 2026 | MCCOURT Thomas A, Officer, Director | 182,185 | $839.9K | 23 Feb 2026 |
| 5 Jan 2026 | RONALD SILVER, Officer | 35,416 | $151.2K | 5 Jan 2026 |
| 14 Nov 2025 | Gaskins Tammi L, Officer | 6,324 | $21.3K | 17 Nov 2025 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 28 Oct 2026 | BANK OF AMERICA CORP /DE/ | 13G amended | 3.2% | 5.2M |
| 14 Aug 2026 | Armistice Capital, LLC | 13G amended | 8.43% | 13.9M |
| 7 Aug 2026 | STATE STREET CORPORATION | 13G | 5.4% | 8.8M |
| 28 Jul 2026 | BlackRock, Inc. | 13G amended | 8.1% | 13.4M |
| 15 May 2026 | Armistice Capital, LLC | 13G amended | 9.22% | 15.0M |
| 14 May 2026 | Renaissance Technologies LLC | 13G amended | 4.9% | 8.1M |
| 27 Apr 2026 | BANK OF AMERICA CORP /DE/ | 13G amended | 6.1% | 10.0M |
| 27 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
| 19 Mar 2026 | Sarissa Capital Management LP | 13D amended | 5.8% | 9.4M |
| 17 Feb 2026 | Armistice Capital, LLC | 13G amended | 9.85% | 16.0M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 15.9M | +2.05% | 7.99 |
| 30 Sep 2026 | 15.6M | -16.88% | 6.19 |
| 15 Sep 2026 | 18.7M | +6.09% | 13.11 |
| 31 Aug 2026 | 17.7M | -2.28% | 11.9 |
| 14 Aug 2026 | 18.1M | +9.21% | 6.44 |
| 31 Jul 2026 | 16.5M | -3.78% | 10.04 |
| 15 Jul 2026 | 17.2M | +5.93% | 6.32 |
| 30 Jun 2026 | 16.2M | +2.08% | 5.65 |
Funds that hold it
From each fund's latest Form 13F.
248 funds held it at 30 Jun 2026: 94 added and 84 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| BlackRock, Inc. | 17,788,557 | $74.9M | +4,425,627 |
| Armistice Capital, LLC | 13,932,000 | $58.7M | -1,096,000 |
| Sarissa Capital Management LP | 9,188,635 | $38.7M | 0 |
| State Street Corp. | 8,809,601 | $37.1M | +1,352,657 |
| Bank of America Corp. | 8,683,803 | $36.6M | +896 |
| Renaissance Technologies LLC | 7,993,226 | $33.7M | -67,847 |
| Vanguard Capital Management LLC | 6,608,508 | $27.8M | +511,054 |
| AQR Capital Management LLC | 6,465,921 | $27.2M | -1,069,159 |
| Acadian Asset Management LLC | 5,853,331 | $24.6M | -723,941 |
| Vanguard Portfolio Management LLC | 5,513,355 | $23.2M | -1,168,682 |
Peers
Companies in the same industry.
- Eli Lilly & Co. (LLY): revenue $86.5B, market value $1.29T
- Johnson & Johnson (JNJ): revenue $99.3B, market value $662.4B
- AbbVie Inc. (ABBV): revenue $64.4B, market value $513.9B
- Merck & Co., Inc. (MRK): revenue $66.6B, market value $361.0B
- Novartis AG (NVS): revenue $54.5B, market value $307.3B
- AstraZeneca PLC (AZN): revenue $58.7B, market value $270.6B
- Abbott Laboratories (ABT): revenue $46.6B, market value $180.9B
- Novo Nordisk A/S (NVO): revenue $46.8B, market value $174.8B
- Pfizer Inc. (PFE): revenue $63.7B, market value $170.7B
- Vertex Pharmaceuticals Inc. (VRTX): revenue $12.6B, market value $136.8B